Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Na-AuPT is a **novel, water-soluble gold(I) complex** developed as a **metal-based proteasome inhibitor** for anticancer therapy. It inhibits both 20S proteasome catalytic subunits and 19S proteasome-associated deubiquitinases (DUBs), thereby **blocking the ubiquitin-proteasome system (UPS)** which is essential for protein degradation in cells. Na-AuPT exerts significant in vitro and in vivo antitumor activity by inducing cell death and apoptosis in a variety of cancer cell lines, and in animal models this compound demonstrated tumor growth inhibition. Mechanistic studies show accumulation of ubiquitinated proteins and activation of apoptosis-related proteins (cleaved caspase 3, Bax). Na-AuPT is a preclinical candidate and, to date, has not been approved or included in advanced clinical trials for human therapy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Na-AuPT.